A phase II trial of homoharringtonine and caracemide in the treatment of patients with advanced large bowel cancer

Investigational New Drugs

Volumn 17, Issue 2, 1999, Pages 173-177

  Witte, Robert S ^a   Lipsitz, Stuart ^b   Goodman, Thomas L ^c   Asbury, Robert F ^d   Wilding, George ^e   Strnad, Charles M ^f   Smith, Thomas J ^g   Haller, Daniel G ^h  

^a GUNDERSEN LUTHERAN MEDICAL CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c Ellis Hospital   (United States)

^d Interlakes Oncology and Hematology PC   (United States)

^e UNIVERSITY OF WISCONSIN   (United States)

^f Natalie Warren Bryant Cancer Center   (United States)

^g MORRISTOWN MEMORIAL HOSPITAL   (United States)

^h HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Colon cancer; Homoharringtonine caracemide

Indexed keywords

CARACEMIDE; HOMOHARRINGTONINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLEEDING; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CANCER; COLORECTAL CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG FATALITY; DRUG TOLERABILITY; FEMALE; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; LEUKOPENIA; LIVER TOXICITY; LUNG DISEASE; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; COHORT STUDIES; COLORECTAL NEOPLASMS; FEMALE; HARRINGTONINES; HUMANS; HYDROXYUREA; MALE; MIDDLE AGED; NEOPLASM STAGING;

EID: 0032762487     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006327418043     Document Type: Article

References (22)

1. Landis SH, Murray T, Bolden S, Wingo PA: Cancer Statistic, 1998. CA Cancer J Clin 48: 6-29, 1998
2. Kemeny N: Current approaches to metastatic colorectal cancer. Semin Oncol 21: 67-75, 1994
3. Conti JA, Kemeny NE, Saltz LB, Huang Y, Tong WP, Chou TC, Sun M, Pulliam S, Gonzalez C: Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 14: 709-715, 1996
4. Rougier P, Bugat R, Douillard JY, Culine S, Suc E, Brunet P, Becouarn Y, Ychou M, Marty M, Extra JM, Vonneterre J, Adenis A, Seitz JZ, Ganem G, Namer M, Conroy T, Negrier S, Merrouche Y, Burki F, Mousseau M, Herait P, Mahjoubi M: Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients treated with fluorouracil-based chemotherapy. J Clin Oncol 15: 251-260, 1997
5. National Cancer Institute Clinical Brochure. Caracemide (NSC 253272). August, 1983
6. Raber MN, Adams F, Kavanagh J, Legha S, Dimery I, Krakoff I: Phase I trial of caracemide using bolus and infusional schedules. Cancer Treat Rep 71: 349-352, 1987
7. Powell RG, Weisleder D, Smith CR Jr, Rohwedder WK: Structures of harringtonine, isoharringtonine, and homoharringtonine. Tetrahedron Letters 11: 815-818, 1970
8. Suffness M, Gordell GA: Antitumor alkaloids. The Alkaloids 25: 1-355, 1985
9. Clinical Brochure: Homoharringtonine (NSC 141633) (IND 19125), IDB, CTEP, DCT, NCI, Bethesda, MD, October, 1997
10. Kantarjian HM, Keating MJ, Walters RS, Koller CA, McCredie KB, Freireich EJ: Phase II study of low-dose continuous infusion homoharringtonine in refractory acute myelogenous leukemia. Cancer 63: 813-817, 1989
11. Stewart JA, Cassileth PA, Bennett JM, O'Connell MJ: Continuous infusion homoharringtonine (NSC 141633) in refractory acute non-lymphocytic leukemia. An ECOG pilot study. Am J Clin Oncol 11: 627-629, 1988
12. Feldman E, Arlin Z, Ahmed T, Mittelman A, Puccio C, Chun H, Cook P, Baskind P: Homoharringtonine is safe and effective for patients with acute myelogenous leukemia. Leukemia 6: 1185-1188, 1992
13. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET et al.: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649-655, 1982
14. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958
15. Feun LJ, Savaraj N, Landy H, Levin H, Lampidis T: Phase II study of homoharringtonine in patients with recurrent primary malignant central nervous system tumors. J Neurooncol 9: 159-163, 1990
16. Runge-Morris MA, Kies MS, Vokes E, Blough R, Weidner L, Knop R, Rowland K: Evaluation of homoharringtonine efficacy in the treatment of squamous cell carcinoma of the head and neck: a phase II Illinois Cancer Council study. Invest New Drugs 7: 269-273, 1989
17. Lad T, Schor J, Mullane M, Carroll R, Chernicoff D, Blough R, Weidner L: Phase II trial of caracemide (NSC 253272) in advanced unresectable non-small cell bronchogenic carcinoma. An Illinois Cancer Council study. Invest New Drugs 10: 27-28, 1992
18. Belani CP, Eisenberger M, Van Echo D, Hiponia D, Aisner J: Phase II study of caracemide in advanced or recurrent non-small cell lung cancer. Cancer Treat Rep 71: 1099-1100, 1987
19. Erlichman C, Fine S, Wong A, Elhakim T: A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 6(3): 469-475, 1988
20. Petrelli N, Douglass HO Jr, Herrera L, Russell D, Stablein DM, Bruckner HW, Mayer RJ, Schinella R, Green MD, Muggia FM, Megibow A, Greenwald ES, Bukowski RM, Harris J, Levin B, Gaynor E, Loutfi A, Kalser MH, Barkin JS, Benedetto P, Woolley PV, Nauta R, Weaver DW, Leichman LP: The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized Phase III trial. J Clin Oncol 7(10): 1419-1426, 1989
21. Doroshow JH, Multhauf P, Leong L, Margolin K, Litchfield T, Akman S, Carr B, Bertrand M, Goldberg D, Blayney D, Odujinrin O, DeLap R, Shuster J, Newman E: Prospective randomized comparison of fluourouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy. J Clin Oncol 8(3): 491-501, 1990
22. Buroker TE, O'Connell MJ, Wieand HS, Krook JE, Gerstner JB, Mailliard JA, Schaefer PL, Levitt R, Kardinal CG, Gesme DH Jr: Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 12(1): 14-20, 1994